Completed PHASE2 INTERVENTIONAL 1-arm NCT00303108

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer

Sponsor: Ortho Biotech, Inc.

Interventions Carboplatin Pegylated liposomal doxorubicin trastuzumab

Updated 6 times since 2017 Last updated: Sep 15, 2016 Started: Dec 31, 2005 Primary completion: Mar 31, 2010 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Breast Cancer and is currently completed. Ortho Biotech, Inc. leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ortho Biotech, Inc.
Tibotec Pharmaceutical Limited
US Oncology Research

Data source: US Oncology Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Albany, United States , Amarillo, United States , Arlington, United States , Beaumont, United States , Bedford, United States , Birmingham, United States , Cary, United States , Chicago, United States , Columbia, United States and 43 more locations